Indeed, without the gene discovery and the clinical trial of targeted therapy in humans, people with KCNJ11 PNDM would have remained on a treatment that was not very efficient and that allowed only suboptimal glycaemic control, leading to increased risk of long-term diabetes complications. This evidence concerns the gene KCNJ11 and diabetes mellitus.